List of Zimhi drug patents

Zimhi is owned by Adamis Pharms Corp.

Zimhi contains Naloxone Hydrochloride.

Zimhi has a total of 2 drug patents out of which 0 drug patents have expired.

Zimhi was authorised for market use on 15 October, 2021.

Zimhi is available in solution;intramuscular, subcutaneous dosage forms.

Zimhi can be used as a method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device; a method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a needle guard; a method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a window configured to allow the user to view the opioid antagonist in the syringe.

The generics of Zimhi are possible to be released after 14 June, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027072 ADAMIS PHARMS CORP Emergency devices
May, 2039

(15 years from now)

US11571518 ADAMIS PHARMS CORP NA
Jun, 2041

(18 years from now)

Do you want to check out ZIMHI patents from before 2022?

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device; A method for administering a therapeutic dose of an opioid antagonist comprising an emerge...

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

ZIMHI family patents

6

United States

1

Korea, Republic of

1

China

1

Israel

1

Canada

1

Japan

1

Australia

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in